Design, Synthesis and Biological Evaluation of Small Molecules to Target <italic>Mycobacterium tuberculosis</italic> Dxr: Exploration of Modified Carbon Chain Lengths and Extended Acyl Substituents
Open AccessTuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is one of the deadliest infectious diseases. Emergence of drug resistant strains of Mtb and co-infection with HIV has made TB both difficult and expensive to treat. New TB therapies are needed to shorten treatment and be effective against all strains and metabolic states of the organism. Development of inhibitors of 1-deoxy-D-xylulose-5-phosphate reducto-isomerase (Dxr), an essential enzyme for Mtb, is a novel approach toward the development of a new TB chemotherapy. Natural product fosmidomycin inhibits Dxr and kills other organisms (Plasmodium falciparum, Escherichia coli) reliant on this enzyme. Interestingly, fosmidomycin is not effective against Mtb. The goals of this work are to rationally design inhibitors that will specifically inhibit Mtb Dxr and enhance cellular uptake. Two series of compounds were designed and synthesized. Compounds from both series inhibit Mtb Dxr and demonstrate enhanced whole cell activity. The synthetic and biological results of this work will be presented.
- All rights reserved
Notice to Authors
If you are the author of this work and you have any questions about the information on this page, please use the Contact form to get in touch with us.